NCCIH Clinical Trials

The information found on our Clinical Trial Requirements for Grants and Contracts pages applies across all NIH institutes, centers, and offices (ICOs). This page provides NCCIH interest areas, types of trials supported, and other funding considerations related to Clinical Trials.

Clinical Trials Interest Areas

  • NCCIH supports a broad spectrum of clinical trial research on complementary and integrative health (CIH) approaches relevant to our mission, with the goals of:
    • Understanding how and for whom these approaches work, and
      • Developing scientific evidence to inform decisions about their use made by the public, health care providers, and others.
    • Clinical trial applications that include a high-priority CIH approach and a high-priority topic of interest will be considered higher programmatic priority for funding. Applications proposing CIH approaches or research topics not identified as high priority can be submitted but may be considered lower programmatic priority, which may reduce the likelihood of funding. 
    • High-priority CIH approaches include:
      • Mind and Body Approaches that include psychological and/or physical components:
        • Psychological approaches (e.g., biofeedback, breathing exercises, guided imagery, hypnosis, meditation, mindfulness techniques, music or other art-based therapies, and progressive relaxation)
        • Physical approaches (e.g., acupuncture, massage therapy, spinal manipulation or mobilization)
        • Combined Physical and Psychological approaches (e.g., dance, qi gong, tai chi, and yoga)
      • Natural Products Approaches that include nutritional or topical components:
        • Botanicals and herbal products
        • Vitamins and minerals
        • Dietary Supplements
        • Probiotics and Prebiotics
        • Other natural products within NCCIH’s research mission
      • Multicomponent and Integrative Interventions including:
        • A CIH approach combined with conventional therapy, such as a natural product plus surgery or yoga plus medication
        • Two or more CIH approaches, such as massage plus biofeedback or a natural product plus mindfulness
        • Whole-system approaches such as naturopathic medicine, traditional Chinese medicine, Ayurvedic medicine, and chiropractic care
        • Integrated models of care in which CIH approaches are substantively incorporated into conventional health care
        • Multilevel interventions involving patients, caregivers, clinicians, family, social systems and/or health care systems when a CIH is included at one or more levels
      • Remotely Delivered Interventions when the CIH approach is delivered partly or entirely through:
        • Mobile health (mHealth) technologies
        • Telephone or videoconferencing
        • Web-based platforms
        • Mobile applications
        • Wearable or other remote technologies
    • High-priority topics of interests for clinical trials that include CIH approaches include:
      • Whole person research: outcomes spanning multiple interconnected domains of health, including physical, psychological, behavioral, and social health; and outcomes across multiple organs or physiological systems
      • Health research: promotion of health behaviors, health restoration, emotional well-being, or resilience
      • Whole person health research combining a whole person approach to the research question and focusing on outcomes related to restoring or promoting health
      • Prevention or management of symptoms and conditions such as:
        • Pain and pain-related conditions (acute and chronic)
        • Sleep and sleep-related disorders/disturbances
        • Mental and behavioral health (e.g., depression, anxiety, chronic stress, and post-traumatic stress/post-traumatic stress disorder)
        • Obesity
      • Reduction of measurable disparities in health outcomes, particularly in pain, obesity, mental and emotional behavioral health, maternal health, and other high-priority symptom and condition areas
      • Enhancement of adherence to medications or prescribed behavioral approaches (e.g., physical activity and healthy eating); 
      • Reduction or deprescribing of inappropriate use of medications or other substances (e.g., drugs of abuse or medications that are contraindicated in specific patient populations) 
      • Reduction in risk for/incidence of HIV or comorbidities, coinfections, and complications from HIV
    • Impact on interoceptive processes relevant to health outcomes.
    • Predictors of therapeutic response: biomarkers and other biological, behavioral, psychological, or social factors associated with differential response to CIH interventions
      • Evaluation of biological, behavioral, psychological, and/or social processes (or their interactions) through which CIH approaches affect clinically relevant outcomes
      • Gut microbiome-brain interactions, particularly in the context of prebiotics, probiotics, and other natural products interventions in clinical populations (e.g., depression, anxiety disorders, IBS, and chronic pain)
      • Reasons for individual differences in response to CIH interventions
      • Evaluation of real-time, “online”, processes that occur during CIH interventions and are relevant to health outcomes
      • For natural product clinical trials, NCCIH places particular emphasis on conditions for which natural products are used by the public and for which there is evidence supporting a postulated mechanism of action
    • Research in Real-World Settings
      • When supported by evidence of efficacy and feasibility, NCCIH is interested in studying the impact of integrating complementary and integrative health interventions into relevant real-world settings, including:
        • Health care systems
        • Public health settings
        • Schools
        • Military and veteran health care settings
        • Community organizations
        • Justice system settings
        • Homeless shelters and other settings serving populations experiencing health disparities
    • Topics NCCIH generally will not support:
      • Multicomponent interventions composed solely of conventional treatments
      • Studies in which the CIH approach is incidental to the intervention rather than a substantive component
      • Studies of digital or remote technologies that do not deliver, support, or evaluate a CIH approach relevant to the NCCIH mission
      • Conventional disease treatment or disease pathophysiology without a substantive CIH research question relevant to the NCCIH mission
      • Trials that propose to test interventions for the treatment or prevention of cancer
      • Diets, macronutrients, or micronutrients studied primarily for their nutritional benefits, rather than as CIH interventions within the NCCIH mission
      • Synthetic pharmaceuticals as the sole intervention

Clinical Trials Types of Trials Supported

  • NCCIH supports clinical trials of complementary and integrative health (CIH) interventions across the continuum of development and testing. Depending on the research question and existing evidence, supported trial types include:
    • Early-phase clinical trials to assess target engagement or identify how CIH approaches work in humans to affect clinically relevant outcomes 
      • Evaluate whether an intervention has a specific, reproducible effect on a hypothesized target, including biological, behavioral, psychological, or social factors relevant to therapeutic responses.
        • Studies should be designed and statistically powered to detect engagement of the hypothesized target, rather than to detect changes in clinical outcomes.
        • Clinical outcomes must be assessed but these trials are not powered to establish clinical efficacy or effectiveness. Thus, efficacy tests should not be proposed. Instead, these trials should examine relationships between target engagement factors and clinical outcomes.
        • Typically supported through the parent Exploratory/Developmental (R21) and parent Research Project (R01), or an Exploratory/Developmental Phase 1 and 2 (R61/R33) or R33 notice of funding opportunity (NOFO).
      • Early-phase clinical trials for CIH interventions that include natural products
        • Trials that establish critical information needed for subsequent clinical testing of natural products, including pharmacokinetics, pharmacodynamics, optimal dose, formulation, or other intervention parameters. 
        • Includes Phase I and II trials.
        • Typically supported through an R61/R33 or R33 NOFO.
      • Feasibility clinical trials for CIH interventions that include mind and body approaches
        • Small-scale single site or multisite studies designed to determine whether the methods and procedures needed for a subsequent larger trial can be successfully implemented. 
        • Appropriate purposes include evaluating feasibility of recruitment, randomization, retention, and adherence strategies, and assessing intervention fidelity, participant burden, acceptability, and credibility. 
        • Typically supported through a Planning Grant (R34) NOFO. 
      • Multi-site efficacy and effectiveness trials, including NIH Phase III Trials: 
        • Efficacy trials are fully powered to determine whether the CIH intervention provides clinical benefit under optimized conditions designed to maximize internal validity. 
        • Effectiveness trials are designed to determine the effects of a CIH intervention under more heterogeneous, “real-world” conditions, generally involving broader participant populations, providers, and/or intervention delivery settings. 
        • Includes comparative efficacy and effectiveness trials testing two or more active interventions. 
        • NCCIH prefers efficacy and effectiveness trials to include multiple sites with geographic diversity. 
        • Typically supported through an Exploratory/Developmental Cooperative Agreement Phase 1 and 2 (UG3/UH3) NOFO.
      • Pragmatic clinical trials: 
        • Trials evaluating CIH interventions when embedded in clinical care or other real-world health care or public health settings. 
        • Interventions must have sufficient prior evidence of efficacy. 
        • Often utilize hybrid effectiveness-implementation designs that simultaneously address whether an intervention works and the effectiveness of strategies used to implement the intervention in real-world settings. 
        • NCCIH prefers pragmatic trials to include multiple sites with geographic diversity.
        • Typically supported through an UG3/UH3 NOFO.
      • Dissemination and implementation clinical trials: 
        • Trials designed to evaluate strategies to promote the adoption, integration, spread, and sustainability of evidence-based CIH interventions in clinical or community settings.
        • Interventions must have sufficient prior evidence of efficacy and effectiveness.
        • Typically supported through an R01 or UG3/UH3 NOFO.
    • NCCIH generally will not support:
      • Trials proposing to deliver an intervention to participants outside the United States or Canada. 
      • Trials using a waitlist comparator condition due to the potential for expectancy effects.
      • Early stage or feasibility trials proposing to compare clinical outcomes between groups to determine “preliminary efficacy” due to concerns that underpowered effect sizes are unstable.
      • For powered efficacy, effectiveness or pragmatic trials:
        • Single site or geographically limited trials.
        • Trials that do not have a minimum of 90 percent power for the primary outcome.
        • Trials that do not have preliminary feasibility data on a similar intervention in a similar population.
      • For powered efficacy, effectiveness or pragmatic trials that include a natural product:
        • Studies that do not include preliminary data to justify the selected dose, bioavailability and safety of the natural product.
        • Studies that do not demonstrate that the natural product can produce a measurable change in target engagement that has been replicated. 

Clinical Trials Project Period Considerations

  • For R61/R33 clinical trial applications:
    • The R61 phase may not exceed 3 years
    • The R33 phase may not exceed 3 years
    • Applications are encouraged to propose a combined project period of up to 5 years when possible. 
    • A maximum of 6 years to complete both phases will be approved when extremely well justified. 
  • For UG3/UH3 applications:
    • The UG3 phase may not exceed 2 years
    • The UH3 phases may not exceed 6 years 
    • Applications are encouraged to propose a combined project period of up to 5 years when possible. 
    • A maximum project period of 7 years to complete both phases will be approved when extremely well justified (e.g., when longer term follow-up is needed). 

Clinical Trials Budget Considerations

  • Feasibility trials should not exceed $250,000 direct costs per year for single site trials and $350,000 direct costs per year for multi-site trials.
  • Early phase clinical trials for target engagement should not exceed $450,000 direct costs per year unless well justified to accommodate specific target engagement measures.
  • Applications to an R61/R33 NOFO should not exceed $350,000 direct costs per year for the R61 phase and $500,000 direct costs per year for the R33 phase unless well justified.
  • Applications to an UG3/UH3 NOFO should not exceed $700,000 direct costs per year for the UG3 phase and $1,000,000 direct costs per year for the UH3 phase unless well justified.

Clinical Trials Contacts


For technical issues E-mail OER Webmaster